In addition, in vitro and in vivo studies indicated that everolimus combined with metformin synergistically inhibited breast cancer cell growth, clonogenicity, PI3K/mTOR signaling activity, mitochondrial respiration, and xenograft tumor growth [34,35]. Here, PIK3CA is linked to breast carcinoma.